Showing results (1071-1080 of 4,366) with videos related to

Sort By:
Pageof 437
Clinical Immunology (Orlando, Fla.)|March 23, 2020
Nine-test panel has superior sensitivity to detect antiphospholipid antibody syndrome in patients with or without SLEKonrad Dziamski, Saika Sharmeen, Katalin Banki, et al.
Clinical Immunology (Orlando, Fla.)|July 31, 2026
KLF4 modulates macrophage-driven inflammation in diabetic psoriasis-like dermatitis through the TIMP3-ADAM17 axis: A basic researchMeichen Jin, Yiyao Li, Yuan Kong, et al.
Clinical Immunology (Orlando, Fla.)|August 28, 2026
TIM-3 as a therapeutic target in anaplastic thyroid carcinoma: Preclinical and transcriptomic evidence supporting a new immunotherapy avenueMonikongkona Boruah, Riyaz Ahmad Mir, Sameer Rastogi, et al.
Clinical Immunology (Orlando, Fla.)|July 17, 2003
Distinct immune profiles characterize patients with diffuse or limited systemic sclerosisFrancesca Ingegnoli, Daria Trabattoni, Marina Saresella, et al.
Clinical Immunology (Orlando, Fla.)|July 17, 2003
Engineered variants of human glutamic acid decarboxylase (GAD) and autoantibody epitope recognitionM E Primo, E A Anton, A L Villanueva, et al.
Clinical Immunology (Orlando, Fla.)|July 17, 2003
The Delta 32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-alpha and ribavirinJ Glas, H P Török, C Simperl, et al.
Clinical Immunology (Orlando, Fla.)|August 19, 2003
IL-4 and many roads to lupuslike autoimmunityRam Raj Singh
Clinical Immunology (Orlando, Fla.)|August 19, 2003
Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytesBonnie Bidinger, Roxabella Torres, Ronald G Rossetti, et al.
Clinical Immunology (Orlando, Fla.)|August 19, 2003
Early hyperbaric oxygen therapy attenuates disease severity in lupus-prone autoimmune (NZB x NZW) F1 miceShao-Yuan Chen, Yen-Chen Chen, Jehng-Kang Wang, et al.
Clinical Immunology (Orlando, Fla.)|August 19, 2003
Virion-bound ICAM-1 and activated LFA-1: a combination of factors conferring resistance to neutralization by sera from human immunodeficiency virus type 1-infected individuals independently of the disease status and phaseMartine Losier, Jean François Fortin, Réjean Cantin, et al.
Pageof 437